Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease

Overview of attention for article published in JAMA Neurology, February 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 4 news outlets
twitter: 262 X users
patent: 1 patent
facebook: 4 Facebook pages

wikipedia: 7 Wikipedia pages
reddit: 1 Redditor
podcasts: 1 podcast

Readers on

mendeley: 299 Mendeley

So far, Altmetric has seen 5 news stories from 4 outlets.

Neurodégénérescence: quand le cerveau a la tête dure - Québec Science

Québec Science, 31 Jul 2020

Santé Les maladies neurodégénératives tiennent tête aux chercheurs. Pour s’extirper du cul-de-sac, les scientifiques explorent…

Two More Alzheimer's Drug Candidates Fail

Medscape, 09 Dec 2019

Two more Alzheimer's drug candidates have been added to the list of failures in trying to find a treatment for the disease.

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.

Alzforum, 22 Nov 2019

Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie…

Alzheimer’s Trial: Lessons From a Failed Drug

MedPage Today, 18 Nov 2019

Minocycline (Minocin), an anti-inflammatory tetracycline that crosses the blood-brain barrier and inhibits proinflammatory…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.